<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012155</url>
  </required_header>
  <id_info>
    <org_study_id>MSKCC-00022</org_study_id>
    <secondary_id>CDR0000068488</secondary_id>
    <secondary_id>MGENE-NR1-001</secondary_id>
    <secondary_id>NCI-G01-1920</secondary_id>
    <nct_id>NCT00012155</nct_id>
  </id_info>
  <brief_title>Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalating Study Of The Safety, Tolerability, And Anti-Tumor Activity Of A Single Intrahepatic Arterial Injection Of Genetically Engineered Herpes Simplex Virus, NV1020, In Subjects With Adenocarcinoma Of The Colon With Metastasis To The Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that&#xD;
      has spread to the liver and has not responded to previous chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and maximum tolerated dose of a single intrahepatic NV1020&#xD;
           injection in patients with hepatic metastases from colon cancer that has failed&#xD;
           first-line chemotherapy.&#xD;
&#xD;
        -  Determine the tolerability of this drug in these patients.&#xD;
&#xD;
        -  Determine preliminarily the anti-tumor activity of this drug in these patients.&#xD;
&#xD;
        -  Assess the immunogenicity of NV1020 in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive a single intrahepatic arterial injection of NV1020 over 10 minutes with the&#xD;
      aid of hepatic arteriography.&#xD;
&#xD;
      Cohorts of 3 patients receive escalating doses of NV1020 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 1, 2, and 3 months post injection. Patients may participate in a&#xD;
      separate long term (up to 1 year) follow-up study for continued assessment and monitoring.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NV1020</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon&#xD;
&#xD;
               -  At least 3 metastatic hepatic lesions involving both lobes&#xD;
&#xD;
               -  No extrahepatic disease&#xD;
&#xD;
          -  Failed first-line combination chemotherapy of fluorouracil plus either leucovorin&#xD;
             calcium or irinotecan&#xD;
&#xD;
          -  Herpes simplex virus type-1 seropositive&#xD;
&#xD;
          -  Candidate for intrahepatic arterial infusion pump placement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9.0 g/dL&#xD;
&#xD;
          -  No history of any blood clotting disorder (e.g., hemophilia)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Transaminases no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No active hepatitis&#xD;
&#xD;
          -  No history of hepatic fibrosis, cirrhosis, or hemochromatosis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  All patients must use effective barrier contraception during and for at least 6 months&#xD;
             after study&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active herpes infection&#xD;
&#xD;
          -  No other active uncontrolled infection&#xD;
&#xD;
          -  No prior weight loss of more than 10 lbs within the past month&#xD;
&#xD;
          -  No history of alcohol or other substance abuse&#xD;
&#xD;
          -  No concurrent unstable and/or severe medical or psychological condition&#xD;
&#xD;
          -  No history of any other medical or psychological condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy (e.g., interleukin-2, interleukin -12, or&#xD;
             interferon)&#xD;
&#xD;
          -  No prior gene transfer therapy&#xD;
&#xD;
          -  No prior therapy with cytolytic virus of any type&#xD;
&#xD;
          -  No concurrent immunotherapy during and for 28 days after study therapy&#xD;
&#xD;
          -  No concurrent vaccines during and for 28 days after study therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No concurrent chemotherapy during and for 28 days after study therapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent systemic steroids during and for 28 days after study therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to the liver&#xD;
&#xD;
          -  No concurrent radiotherapy during and for 28 days after study therapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior participation in investigational study&#xD;
&#xD;
          -  No concurrent antiviral agent active against herpes simplex virus (e.g., acyclovir,&#xD;
             valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, or cidofovir) during&#xD;
             and for 28 days after study therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive agents (e.g., cyclosporine) during and for 28 days&#xD;
             after study therapy&#xD;
&#xD;
          -  No other concurrent investigational or anti-cancer agents during and for 28 days after&#xD;
             study therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuman Fong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kemeny N, Jarnagin W, Guilfoyle B, et al.: Results of a phase I, dose-escalating study of the safety, tolerability and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, nv1020, in subjects with hepatic colorectal metastases. [Abstract] Ann Oncol 16 (Suppl 2): A-480, ii283, 2005.</citation>
  </results_reference>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>June 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

